Novo Nordisk has agreed to pay nearly $59 million to settle seven whistleblower lawsuits accusing the Danish multinational drug company of violating the Federal Food, Drug, and Cosmetic Act (FDCA) and False Claims Act (FCA) by downplaying the health risks of its diabetes drug Victoza. The U.S. Justice Department said Tuesday’s settlement settles allegations that Novo Nordisk fed information to doctors through its sales force that created false or misleading impressions that the U.S. Food and Drug Administration (FDA)-mandated warnings for Victoza were wrong or unimportant. After the FDA approved Victoza as a Type II diabetes treatment in 2010, it required ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.